Literature DB >> 24533227

Helper-Dependent Adenoviral Vectors.

Amanda Rosewell1, Francesco Vetrini1, Philip Ng1.   

Abstract

Helper-dependent adenoviral vectors are devoid of all viral coding sequences, possess a large cloning capacity, and can efficiently transduce a wide variety of cell types from various species independent of the cell cycle to mediate long-term transgene expression without chronic toxicity. These non-integrating vectors hold tremendous potential for a variety of gene transfer and gene therapy applications. Here, we review the production technologies, applications, obstacles to clinical translation and their potential resolutions, and the future challenges and unanswered questions regarding this promising gene transfer technology.

Entities:  

Year:  2011        PMID: 24533227      PMCID: PMC3923448          DOI: 10.4172/2157-7412.s5-001

Source DB:  PubMed          Journal:  J Genet Syndr Gene Ther        ISSN: 2157-7412


  180 in total

1.  An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.

Authors:  A I Kuzmin; O Galenko; R C Eisensmith
Journal:  Mol Ther       Date:  2001-03       Impact factor: 11.454

2.  Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo.

Authors:  Daniel M Appledorn; Sonika Patial; Aaron McBride; Sarah Godbehere; Nico Van Rooijen; Narayanan Parameswaran; Andrea Amalfitano
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

3.  A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging.

Authors:  R J Parks; F L Graham
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

Authors:  N Morral; W O'Neal; H Zhou; C Langston; A Beaudet
Journal:  Hum Gene Ther       Date:  1997-07-01       Impact factor: 5.695

5.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

6.  Antigen-specific tolerance of human alpha1-antitrypsin induced by helper-dependent adenovirus.

Authors:  V Cerullo; W McCormack; M Seiler; V Mane; R Cela; C Clarke; J R Rodgers; B Lee
Journal:  Hum Gene Ther       Date:  2007-12       Impact factor: 5.695

7.  Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; K Dee Carey; Milton Finegold; Philip Ng
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

8.  A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.

Authors:  Hua Li; Shih-Wen Lin; Wynetta Giles-Davis; Yan Li; Dongming Zhou; Zhi Quan Xiang; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

9.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study.

Authors:  R H Simon; J F Engelhardt; Y Yang; M Zepeda; S Weber-Pendleton; M Grossman; J M Wilson
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

10.  Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Authors:  A K M G Muhammad; M Puntel; M Candolfi; A Salem; K Yagiz; C Farrokhi; K M Kroeger; W Xiong; J F Curtin; C Liu; K Lawrence; N S Bondale; J Lerner; G J Baker; D Foulad; R N Pechnick; D Palmer; P Ng; P R Lowenstein; M G Castro
Journal:  Clin Pharmacol Ther       Date:  2010-02-17       Impact factor: 6.875

View more
  7 in total

Review 1.  Current development in adenoviral vectors for cancer immunotherapy.

Authors:  Greyson Willis Grossman Biegert; Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Mol Ther Oncolytics       Date:  2021-11-20       Impact factor: 7.200

Review 2.  Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges.

Authors:  Sumit Ghosh; Alex M Brown; Chris Jenkins; Katie Campbell
Journal:  Appl Biosaf       Date:  2020-03-01

Review 3.  Viral Delivery Systems for CRISPR.

Authors:  Christine L Xu; Merry Z C Ruan; Vinit B Mahajan; Stephen H Tsang
Journal:  Viruses       Date:  2019-01-04       Impact factor: 5.048

Review 4.  Genetic Delivery and Gene Therapy in Pulmonary Hypertension.

Authors:  Nabham Rai; Mazen Shihan; Werner Seeger; Ralph T Schermuly; Tatyana Novoyatleva
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

5.  iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy.

Authors:  Dominik Brücher; Nicole Kirchhammer; Sheena N Smith; Jatina Schumacher; Nina Schumacher; Jonas Kolibius; Patrick C Freitag; Markus Schmid; Fabian Weiss; Corina Keller; Melanie Grove; Urs F Greber; Alfred Zippelius; Andreas Plückthun
Journal:  Mol Ther Methods Clin Dev       Date:  2021-01-20       Impact factor: 6.698

Review 6.  Gene therapy approaches for equine osteoarthritis.

Authors:  Parvathy Thampi; R Jude Samulski; Joshua C Grieger; Jennifer N Phillips; C Wayne McIlwraith; Laurie R Goodrich
Journal:  Front Vet Sci       Date:  2022-09-28

7.  Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies.

Authors:  Chang Li; Nikoletta Psatha; Hongjie Wang; Manvendra Singh; Himanshu Bhusan Samal; Wenli Zhang; Anja Ehrhardt; Zsuzsanna Izsvák; Thalia Papayannopoulou; André Lieber
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.